Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

December 15, 2025

Study Completion Date

October 31, 2026

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine and Venetoclax

Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.

Trial Locations (1)

80045

University of Colorado Denver, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER